(-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine Chemical and Physical Properties

Names and Identifiers

- (-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine
- (-)1-[1-(4-chlorophenyl) phenylmethyl]piperazine
- (-)-1-[(4-Chlorophenyl)phenylmethyl]piperzine
- (-)-1-[(4-CHLOROPHENYL)PHENYLMETHL]PIPERAZINE
- (-)-1-[1-(4-CHLOROPHENYL)PHENYLMETHYL] PIPERAZINE
- (R)-1-(p-Chlorobenzhydryl)piperazine
- CPP_287.1310_14.5
- CETIRIZINE DIHYDROCHLORIDE IMPURITY A [EP IMPURITY]
- NS00000628
- Oprea1_771131
- N-(4-Chlorobenzhydryl)piperazine
- Norchlorcyclizine
- DTXSID00891490
- (-)-1-[(4-Chloro-phenyl)-phenyl-methyl]-piperazine
- SB47944
- NSC-86164
- AMY40892
- N-[(4-chlorophenyl)(phenyl)-methyl]piperazine
- GF-0133
- (-)-1-[1-(4-Chlorophenyl)Phenylmethyl]piperazine
- 1-(4-Chlorobenzhydryl)piperazine, technical grade, 90%
- MECLOZINE DIHYDROCHLORIDE IMPURITY H [EP IMPURITY]
- chlorobenzhydryl piperazine
- Piperazine, 1-[.alpha.-(4-chlorophenyl)benzyl]-
- GTPL9162
- FT-0629215
- (R)-Cetirizine EP Impurity A;(R)-1-((4-Chlorophenyl)(phenyl)methyl)piperazine
- Q27076864
- A806004
- 1-[(4-Chlorophenyl)phenylmethyl]piperazine
- 1-((4-chlorophenyl)(phenyl)methyl)piperazine
- Cetirizine impurity A, European Pharmacopoeia (EP) Reference Standard
- NSC86164
- 4-(4-Chlorobenzhydryl)piperazine
- BCP34517
- SR-01000597190-1
- (+/-)-1-(P-CHLOROBENZHYDRYL)PIPERAZINE
- Meclozine impurity H, European Pharmacopoeia (EP) Reference Standard
- NSC 86164
- HMS2464F07
- FT-0658637
- 1-[(4-Chlorophenyl)(phenyl)methyl]piperazine
- (S)-Nor-CCZ
- EU-0099994
- 1-[(4-Chloro-phenyl)-phenyl-methyl]-piperazine
- Meclozine impurity H
- NCGC00245963-01
- C 10C10
- Q-200042
- AKOS000268792
- NORCHLORCYCLIZINE, (+/-)-
- CHEMBL81324
- 1-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazine
- Piperazine, 1-(.alpha.-(4-chlorophenyl)benzyl)-
- Piperazine, 1-(p-chloro-.alpha.-phenylbenzyl)-
- Piperazine, 1-((4-chlorophenyl)phenylmethyl)-
- HMS1648P05
- CBHP
- 1-(4-Chlorodiphenylmethyl)piperazine
- FT-0604324
- 303-26-4
- HYDROXYZINE HYDROCHLORIDE IMPURITY A [EP IMPURITY]
- EINECS 206-137-4
- MLS000521343
- (-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine
- C1611
- 1-(4-Chloro-.alpha.-phenylbenzyl)piperazine
- Piperazine, 1-(alpha-(4-chlorophenyl)benzyl)-
- 1-(4-Chlorobenzhydryl) piperazine
- 1-[(4-chlorophenyl)phenylmethyl)piperazine
- N-(4-Chlorophenyl)phenylmethylpiperazine
- AC-3019
- T875VN0D6E
- (-)-1-[(4chlorophenyl) phenylmethyl]piperazine
- 1-[(4-chlorophenyl)-phenyl-methyl]piperazine
- 130018-88-1
- Z57388987
- 1-[(4-chlorophenyl)-phenylmethyl]piperazine
- FT-0604325
- EN300-18220
- (-)-1-[(4-chloro phenyl)phenylmethyl]piperazine
- UNII-T875VN0D6E
- SY003580
- 1-(.alpha.-Phenyl-4-chlorobenzyl)piperazine
- N-(p-Chlorobenzhydryl)piperazine
- 4-CHLOROBENZHYDRYLPIPERAZINE
- 4-23-00-00072 (Beilstein Handbook Reference)
- 1-(4-Chlorobenzhydryl)piperazine
- 1-(4-Chloro-alpha-phenylbenzyl)piperazine
- CS-W001978
- FT-0664913
- SCHEMBL467086
- AKOS016039386
- Cetirizine Impurity A
- BRN 0243027
- 1-((4-chlorophenyl)phenylmethyl)piperazine
- PIPERAZINE, 1-(p-CHLORO-alpha-PHENYLBENZYL)-
- 1-[(4-Chlorophenyl)phenylmethyl]-piperazine-D8
- 1-[(4-chlorophenyl)-phenylmethyl]-piperazine
- SR-01000597190
- Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-
- Levocetirizine Impurity 2
- MFCD00005965
- compound C10 [PMID: 24297249]
- HY-W001978
- BCP08791
- (RS)-1-[(4-Chlorophenyl)phenylmethyl]piperazine
- 4-chlorobenzhydryl piperazine
- SMR000131751
- CETIRIZINE HYDROCHLORIDE IMPURITY CBHP [USP IMPURITY]
- 1-(alpha-Phenyl-4-chlorobenzyl)piperazine
- 1-((4-Chlorophenyl)(phenyl)methyl)-piperazine
- DB-018556
- (S)-1-((4-chlorophenyl)(phenyl)methyl)piperazine
- BBL010366
- GLXC-04310
- STK083473
- (R)-(-)-1-[(4-Chlorophenyl)phenylmethyl]piperazine
- Inchi： 1S/C17H19ClN2/c18-16-8-6-15(7-9-16)17(14-4-2-1-3-5-14)20-12-10-19-11-13-20/h1-9,17,19H,10-13H2
- InChI Key： UZKBSZSTDQSMDR-UHFFFAOYSA-N
- SMILES： ClC1C=CC(=CC=1)C(C1C=CC=CC=1)N1CCNCC1

Computed Properties

Exact Mass: 286.12400
Monoisotopic Mass: 286.124
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 1
Hydrogen Bond Acceptor Count: 2
Heavy Atom Count: 20
Rotatable Bond Count: 3
Complexity: 277
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count : 1
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Topological Polar Surface Area: 15.3A^2
XLogP3: 3.4

Experimental Properties

Color/Form: No data avaiable
Density: 1.2±0.1 g/cm3
Melting Point: No data available
Boiling Point: 409.1±0.0 °C at 760 mmHg
Flash Point: 193.3±26.5 °C
Refractive Index: 1.58
PSA: 15.27000
LogP: 3.60130
Vapor Pressure: No data available

(-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine Security Information

Signal Word：Warning
Hazard Statement： H302 (23.64%) H315 (92.73%) H319 (92.73%)
Warning Statement： P264+P280+P305+P351+P338+P337+P313
Safety Instruction： H302 (23.64%) H315 (92.73%) H319 (92.73%)
Storage Condition：Store at 4 ° C, -4 ° C is better

(-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
A2B Chem LLC	AV15628-250mg	1-[(R)-(4-Chlorophenyl)-phenyl-methyl]piperazine	130018-88-1		250mg	$92.00	2024-01-04
A2B Chem LLC	AV15628-1g	1-[(R)-(4-Chlorophenyl)-phenyl-methyl]piperazine	130018-88-1	99%	1g	$403.00	2024-04-20
A2B Chem LLC	AV15628-5g	1-[(R)-(4-Chlorophenyl)-phenyl-methyl]piperazine	130018-88-1		5g	$427.00	2024-01-04
A2B Chem LLC	AV15628-10g	1-[(R)-(4-Chlorophenyl)-phenyl-methyl]piperazine	130018-88-1		10g	$750.00	2024-01-04

(-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine Suppliers

Suzhou Senfeida Chemical Co., Ltd

Gold Member

Audited Supplier

(CAS:130018-88-1)(-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine

Order Number:sfd13000

Stock Status:in Stock

Quantity:200kg

Purity:99.9%

Pricing Information Last Updated:Friday, 19 July 2024 14:36

Price ($):discuss personally

Email:[email protected]

Product Official Link

(-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine Related Literature

1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?

Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?

Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?

Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
4. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?

Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?

Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Additional information on (-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine

Recent Advances in the Study of (-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine (CAS: 130018-88-1)

The compound (-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine (CAS: 130018-88-1) has recently gained significant attention in the field of chemical biology and pharmaceutical research. This chiral piperazine derivative has shown promising pharmacological properties, particularly in the context of central nervous system (CNS) disorders. Recent studies have focused on its potential as a modulator of neurotransmitter systems, with special emphasis on its interactions with dopamine and serotonin receptors.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that (-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine exhibits high affinity for D2-like dopamine receptors, with a Ki value of 12.3 nM. The research team utilized molecular docking simulations to elucidate the compound's binding mode, revealing key interactions with conserved residues in the orthosteric binding site. These findings suggest potential applications in the treatment of Parkinson's disease and schizophrenia, although further in vivo studies are required to validate these therapeutic possibilities.

Another significant development comes from a recent patent application (WO2023056123) that describes novel synthetic routes for (-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine. The improved synthesis features a stereoselective reduction step with up to 98% enantiomeric excess, addressing previous challenges in obtaining the pure (-)-enantiomer. This advancement in synthetic methodology is expected to facilitate more extensive pharmacological evaluation of the compound and its derivatives.

Pharmacokinetic studies published in Xenobiotica (2024) have provided new insights into the metabolic fate of (-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine. The compound demonstrates favorable blood-brain barrier penetration with a brain-to-plasma ratio of 3.2 in rodent models. However, researchers identified extensive first-pass metabolism mediated primarily by CYP3A4, suggesting potential drug-drug interactions that must be considered in clinical applications.

Emerging research presented at the 2024 American Chemical Society National Meeting highlighted the compound's potential as a scaffold for developing novel antidepressants. Structure-activity relationship studies have identified specific modifications to the piperazine core that can enhance selectivity for serotonin transporter (SERT) while minimizing off-target effects. These findings open new avenues for developing next-generation antidepressant medications with improved efficacy and safety profiles.

Recent toxicological evaluations (Regulatory Toxicology and Pharmacology, 2024) have established preliminary safety data for (-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine. The compound showed no significant genotoxicity in standard assays and demonstrated an acceptable therapeutic index in acute toxicity studies. However, chronic toxicity data remain limited, and further investigations are ongoing to fully characterize the compound's safety profile.

The growing body of research on (-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine underscores its potential as a valuable pharmacological tool and potential therapeutic agent. Future research directions likely include optimization of its pharmacokinetic properties, exploration of additional therapeutic indications, and development of more efficient synthetic routes to support large-scale production.

国产一区二区制服丝袜_一级特黄高清完整大片_欧美.亚洲.日韩.另类.av_黄又色又污又爽又高潮动态图_91夫妻视频电影观看_在线手机亚洲中文字幕_国产中文字幕不卡在线_国产乱妇乱子在线播视频播放网站_gogo裸体艺术中国日本

Cas no 130018-88-1 ((-)-1-[(4-Chlorophenyl) Phenylmethyl] Piperazine)